Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051322 | 0.95 | MAPK14 (0.57) | MAPK14HDAC6MAPK11KCNH2HRH3 | |
| SCHEMBL3054889 | 0.89 | MAPK14 (0.59) | MAPK14HDAC6MAPK11CYP3A4 | |
| SCHEMBL4514200 | 0.84 | MAPK14 (0.61) | MAPK14MAPK11KCNH2HRH3 | |
| SCHEMBL3048771 | 0.81 | HDAC6 (0.50) | MAPK14HDAC6ALDH1A1 | |
| SCHEMBL3054080 | 0.81 | MAPK14 (0.58) | MAPK14MAPK11ALDH1A1TSHR | |
| SCHEMBL3053804 | 0.80 | HDAC6 (0.49) | MAPK14HDAC6CYP3A4 | |
| SCHEMBL3063360 | 0.80 | MAPK14 (0.57) | MAPK14MAPK11 | |
| SCHEMBL4502790 | 0.79 | MAPK14 (0.59) | MAPK14MAPK11KCNH2HRH3 | |
| SCHEMBL3048385 | 0.74 | MAPK14 (0.65) | MAPK14MAPK11 | |
| SCHEMBL3050591 | 0.73 | MAPK14 (0.68) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | claimed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 21/4885HDAC6 267/4885MAPK11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.